GRN163L (Imetelstat)

GRN163L, also known as Imetelstat, is an experimental drug being studied primarily for the treatment of certain blood disorders, such as myelofibrosis and essential thrombocythemia. It works by targeting and inhibiting a specific enzyme related to the replication of cancerous cells, which may help slow down or stop their growth. Researchers are investigating its effectiveness and safety through clinical trials, aiming to provide new treatment options for patients with these conditions. It's part of a broader effort to improve therapies for blood-related cancers and disorders.